1 completed. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Progression Free Survival: new trials by email Literature Review of Progression Free Survival trials Research Report on Progression Free Survival
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer Osimertinib, docetaxel, bevacizumab - Progression Free Survival | Phase 2 / Phase 3 | Completed | Qingdao Central Hospital | 147 | 2015-08-01 | 2018-02-14 |
Bevacizumab (1) · Docetaxel (1) · osimertinib (1)
China (1)